BACKGROUND: Persistent Staphylococcus aureus bacteremia (pSAB) is an emerging problem among hospitalized patients. We studied key clinical characteristics and outcomes associated with pSAB to better define the epidemiological features of this increasingly recognized clinical entity. METHODS: A retrospective case-control study of patients hospitalized with SAB between January 1, 2001, and September 30, 2004, was conducted to compare the clinical characteristics, management, and outcomes of patients with pSAB (> 7 days of bacteremia) with those of a cohort of patients with nonpersistent SAB (< 3 days of bacteremia). Patients with 4 to 6 days of bacteremia were excluded from the analysis. To detect a potential association between reduced susceptibility to vancomycin and persistent methicillin-resistant SAB, vancomycin susceptibilities were confirmed using standard dilution methods. RESULTS: Eighty-four patients with pSAB and 152 patients with nonpersistent SAB were included in the analysis. Methicillin resistance (odds ratio [OR], 5.22; 95% confidence interval [CI], 2.63-10.38), intravascular catheter or other foreign body use (OR, 2.37; 95% CI, 1.11-3.96), chronic renal failure (OR, 2.08; 95% CI, 1.09-3.96), more than 2 sites of infection (OR, 3.31; 95% CI, 1.17-9.38), and infective endocarditis (OR, 10.30; 95% CI, 2.98-35.64) were independently associated with pSAB. The mean time to device removal was significantly longer in patients with pSAB than in patients with nonpersistent SAB (4.94 vs 1.64 days; P < .01). There was no evidence of reduced vancomycin susceptibility among persistent methicillin-resistant S aureus isolates. Clinical outcomes were significantly worse among patients with pSAB. CONCLUSIONS: Many hospitalized patients may be at risk for pSAB. Aggressive attempts to minimize the risk of complications and poor outcomes associated with pSAB, such as early device removal, should be encouraged.
BACKGROUND: Persistent Staphylococcus aureus bacteremia (pSAB) is an emerging problem among hospitalized patients. We studied key clinical characteristics and outcomes associated with pSAB to better define the epidemiological features of this increasingly recognized clinical entity. METHODS: A retrospective case-control study of patients hospitalized with SAB between January 1, 2001, and September 30, 2004, was conducted to compare the clinical characteristics, management, and outcomes of patients with pSAB (> 7 days of bacteremia) with those of a cohort of patients with nonpersistent SAB (< 3 days of bacteremia). Patients with 4 to 6 days of bacteremia were excluded from the analysis. To detect a potential association between reduced susceptibility to vancomycin and persistent methicillin-resistant SAB, vancomycin susceptibilities were confirmed using standard dilution methods. RESULTS: Eighty-four patients with pSAB and 152 patients with nonpersistent SAB were included in the analysis. Methicillin resistance (odds ratio [OR], 5.22; 95% confidence interval [CI], 2.63-10.38), intravascular catheter or other foreign body use (OR, 2.37; 95% CI, 1.11-3.96), chronic renal failure (OR, 2.08; 95% CI, 1.09-3.96), more than 2 sites of infection (OR, 3.31; 95% CI, 1.17-9.38), and infective endocarditis (OR, 10.30; 95% CI, 2.98-35.64) were independently associated with pSAB. The mean time to device removal was significantly longer in patients with pSAB than in patients with nonpersistent SAB (4.94 vs 1.64 days; P < .01). There was no evidence of reduced vancomycin susceptibility among persistent methicillin-resistant S aureus isolates. Clinical outcomes were significantly worse among patients with pSAB. CONCLUSIONS: Many hospitalized patients may be at risk for pSAB. Aggressive attempts to minimize the risk of complications and poor outcomes associated with pSAB, such as early device removal, should be encouraged.
Authors: Clare E Miller; Rahul Batra; Ben S Cooper; Amita K Patel; John Klein; Jonathan A Otter; Theodore Kypraios; Gary L French; Olga Tosas; Jonathan D Edgeworth Journal: Clin Infect Dis Date: 2011-12-20 Impact factor: 9.079
Authors: C K Kang; Y K Kim; S-I Jung; W B Park; K-H Song; K-H Park; P G Choe; H-C Jang; S Lee; Y-S Kim; Y G Kwak; K T Kwon; S Kiem; C-J Kim; E S Kim; H B Kim Journal: Eur J Clin Microbiol Infect Dis Date: 2017-06-21 Impact factor: 3.267
Authors: Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong Journal: Antimicrob Agents Chemother Date: 2010-11-22 Impact factor: 5.191
Authors: Henry Wong; Christine Watt; Sameer Elsayed; Michael John; Glen Johnson; Kevin Katz; Sigmund Krajden; Christine Lee; Tony Mazzulli; Krystyna Ostrowska; David Richardson; Baldwin Toye; Christie Vermeiren; Deborah Yamamura; Andrew E Simor Journal: Can J Infect Dis Med Microbiol Date: 2014-03 Impact factor: 2.471
Authors: Julius Li; Kelly L Echevarria; Darrel W Hughes; Jose A Cadena; Jason E Bowling; James S Lewis Journal: Antimicrob Agents Chemother Date: 2014-06-16 Impact factor: 5.191
Authors: S-Y Park; Y P Chong; H J Park; K-H Park; S M Moon; J-Y Jeong; M-N Kim; S-H Kim; S-O Lee; S-H Choi; J H Woo; Y S Kim Journal: Infection Date: 2012-10-12 Impact factor: 3.553